Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Wednesday, 8 May 2019, 20:15 HKT/SGT
Share:
    

Source: Jacobson Pharma Corporation Limited
Jacobson Pharma and Yunnan Baiyao Group to Continue Exploring Further Possibilities of Business Cooperation and Other Collaborations

HONG KONG, May 8, 2019 - (ACN Newswire) - Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the "Group"; Stock Code: 2633), a leading company engaging in the research, development, production, marketing and sale of generic drugs and proprietary medicines, has been informed by Yunnan Baiyao Holdings Company Limited1 ("Baiyao Holdings") and Yunnan Baiyao Group Co.,Ltd. ("Yunnan Baiyao Group") that Baiyao Holdings will be merged into and absorbed by Yunnan Baiyao Group. Currently, Baiyao Holdings holds 200,000,000 shares of Jacobson Pharma, representing approximately 9.92% of the total number of the Group's issued shares. Upon completion of the merger, such 200,000,000 shares are to be held by Yunnan Baiyao Group as the merged entity. Yunnan Baiyao Group is also to actively accelerate exploring potential business cooperation as stated in the letter of intent previously agreed with Jacobson Pharma.

Yunnan Baiyao Group is a renowned and respected brand and a leading company which has developed 16 pharmaceutical dosage forms with more than 370 products. The company initiated the merger proposal in October 2018 which was approved by the China Securities Regulatory Commission in late April 2019, approving it to issue shares as it absorbs Yunnan Baiyao. After the completion of the merger, Yunnan Baiyao Group's operating income is expected to grow to more than RMB27 billion. With its strong financial strength, Yunnan Baiyao Group could leverage its brand, channel and medical resources through in-licensing, strategic cooperation, new product development as well as mergers and acquisitions to fuel business expansion and reinforce competitive strengths.

Jacobson Pharma has pre-eminent leadership in generics, specialty drugs and proprietary medicines in the industry. Backed by a vertically-integrated value chain and advanced production facilities, and bolstered by its robust product portfolio, the Group has one of the most extensive sales and distribution networks covering both the private and public market sectors in Hong Kong. Meanwhile, with Hong Kong as its base, Jacobson Pharma has set to expand its regional platform and is poised to strategically collaborate with reputable manufacturers globally for establishing footholds in Asia Pacific including China, Korea, Japan, Taiwan, Singapore, Malaysia, Cambodia, Myanmar, Thailand and Vietnam.

Jacobson Pharma has previously entered into a letter of intent with Baiyao Holdings pursuant to which the parties agreed to conduct feasibility studies on possible business cooperation and other collaborations. In the future, the Group will continue to actively examine such further possibilities with Baiyao Holdings to broaden and deepen its market coverage in China and Asia Pacific in forging a competitive regional commercial platform aiming to deliver sustainable values for shareholders.

About Jacobson Pharma Corporation Limited (Stock Code: 2633)
Jacobson Pharma is the largest generic drug company in Hong Kong with over 30% share of the total generic drug market for each year since 2012. The Group's proprietary medicines, notably being Po Chai Pills, Tong Tai Chung Woodlok Oil, Ho Chai Kung Tji Thung San, Contractubex Scar Gel Doan's Ointment, Flying Eagle Wood Lok Medicated Oil, Saplingtan, Shiling Oil and Col-gan Tablet have been widely recognized by the market. Jacobson Pharma has been a constituent of MSCI Hong Kong Micro Cap Index since 1 June 2017. For more details about Jacobson Pharma, please visit the Group's website: http://www.jacobsonpharma.com

For media enquiries, please contact:
Strategic Financial Relations Limited
Vicky Lee Tel: (852) 2864 4834 Email: [email protected]
Stephanie Liu Tel: (852) 2864 4852 Email: [email protected]
Tika Lum Tel: (852) 2864 4806 Email: [email protected]
Fax: (852) 2527 1196




May 8, 2019 20:15 HKT/SGT
Topic: Press release summary
Sectors: Daily Finance, Daily News, HealthCare
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2019 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Jacobson Pharma Corporation Limited
May 2, 2019 22:39 HKT/SGT
Jacobson Pharma Issues Positive Profit Alert
Nov 21, 2018 22:43 HKT/SGT
Jacobson Pharma Announces FY2019 Interim Results
June 25, 2018 22:00 HKT/SGT
Jacobson Pharma Announces 2018 Annual Results
June 25, 2018 20:48 HKT/SGT
Jacobson Pharma Announces 2018 Annual Results
June 14, 2018 06:00 HKT/SGT
Jacobson Pharma Updates on TAILORx Study
June 13, 2018 23:50 HKT/SGT
Jacobson Pharma Updates on TAILORx Study
Apr 17, 2018 20:45 HKT/SGT
Jacobson Pharma Ranked No.1 in "Hong Kong Best Small-Cap Company" in the "Asia's Best Companies Poll 2018" by FinanceAsia
Apr 17, 2018 18:30 HKT/SGT
Jacobson Pharma Ranked No. 1 in "Hong Kong Best Small-Cap Company" in the "Asia's Best Companies Poll 2018" by FinanceAsia
Dec 20, 2017 23:00 HKT/SGT
Jacobson Pharma Enters Agreements with Shanghai Henlius Biotech Inc. To Tap Biologics Market
Dec 20, 2017 21:58 HKT/SGT
Jacobson Pharma Enters Agreements with Shanghai Henlius Biotech Inc. To Tap Biologics Market
More news >>
 News Alerts
Copyright © 2019 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 400 879 3881 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6721 7212

Connect With us: